+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Allergy Treatment Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

  • PDF Icon


  • 125 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4895986
UP TO OFF until Sep 30th 2022
The allergy treatment market is expected to register a CAGR of 6.48% during the forecast period.

During the COVID-19 pandemic, a large section of people were struggling with chronic respiratory issues, such as respiratory allergies, including allergic rhinitis and sinusitis. For instance, in a survey conducted by the Asthma and Allergy Foundation of America in June 2020, 2,695 people participated, out of which 57% had asthma, 51% had a family member with asthma, 63% had allergies, and 66% had a family member with allergies. The impact of COVID-19 is considered positive on the market.

The increasing burden of various types of allergies, growing investment by manufacturers on the development of novel allergic treatments, and rising importance for self-medication are the major factors propelling the market's growth. A 2020 report by the Food Allergy Research & Education estimates that 32 million US residents have food allergies, including 5.6 million children under age 18. About 40% of children with food allergies are allergic to more than one food item.

As per the data published by the American College of Allergy, Asthma & Immunology, allergies are the sixth leading cause of chronic illness in the United States, with an annual cost of more than USD 18 billion and more than 50 million Americans suffer from allergies each year. Food allergies among both children and adults are increasing in all parts of the world. Thus, this surge in the burden of allergic diseases is expected to increase the demand for allergy treatment. Moreover, the increasing focus on R&D to develop novel products to cater to high unmet medical needs is highly impacting the market’s growth. For instance, in April 2020, Menlo Therapeutics Inc. reported positive results from its two ongoing Phase-III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for treating Pruritus, a type of treatment of skin allergy.

The population has increasingly adopted the trend of self-medication in developed and developing countries. Thus, there was an increase in the demand for over-the-counter (OTC) drugs over the past decade. These OTC drugs are cheaper and more accessible, which directly increases the procurement of these drugs. All such factors are expected to propel the market during the forecast period. However, growing preference for low-cost biosimilar and lack of awareness regarding allergy immunotherapy can hamper the market’s growth.

Key Market Trends

Subcutaneous Immunotherapy (SCIT) is Expected to Register a High Growth Rate During the Forecast Period

Subcutaneous immunotherapy (SCIT) is the most effective and widely used allergy immunotherapy. So far, SCIT is the only treatment that alters the immune systems and brings systemic relief. SCIT helps prevent the further development of new allergies and asthma.

The innovative launch of immunotherapy products and rising approval are the major factors boosting the market's growth. For instance, recently, in May 2020, Stallergenes Greer announced that Alustal, a subcutaneous allergen immunotherapy (SCIT) solution, will be available in Italy and Spain following the full resumption of SCIT production in Antony (France). Alustal will also be available in Australia, France, and Switzerland in the coming months.​

The various research studies are conducted to demonstrate SCIT safety and efficacy in the adult and pediatric populations. For instance, according to Karger Journal’s article titled ‘Subcutaneous Allergen-Specific Immunotherapy Is Safe in Pediatric Patients with Allergic Rhinitis’ published in June 2021, subcutaneous allergen-specific immunotherapy (SCIT) is one of the main cornerstones in the treatment of allergic rhinitis in pediatric patients. It is also safe and effective. Thus, this research study is expected to drive the growth over the forecast period.​Thus, the rising burden of allergies and the growing adoption of immunotherapy among the population are expected to drive the market’s growth.

North America is Expected to Dominate the Allergy Treatment Market

North America is expected to dominate the market, accounting for the highest share, and it is anticipated to maintain this trend throughout the forecast period. According to an article published in JAMA Network Open Journal, an estimated 10.8% were food allergic in the survey, whereas nearly 19% of adults believed they were food allergic. Nearly half of food-allergic adults had at least one adult-onset food allergy, and 38% reported at least one food allergy-related emergency department visit in their lifetime. According to the Centers for Disease Control and Prevention (CDC), around 10,328,879 people in the United States had an asthma attack in 2019. The increasing allergic attacks demand adequate care to provide proper treatment, thus, boosting the allergy treatment market.​ As per the American Academy of Allergy Asthma and Immunology, sesame was the ninth-most common food allergy in the United States. This prevalence is very high, and it is anticipated to increase in the future.

Apart from the United States, the government of Canada is also focusing on providing Canadians with the information they require to make healthy and safe food choices. The CFIA (Canadian Food Inspection Agency) and Health Canada work jointly with provincial, municipal, and territorial partners and industries to reach this goal.

Moreover, in the United States, numerous drugs are under development, primarily to treat various types of allergies. Market players are focusing on the development and launch of new products. In January 2020, the US FDA approved Palforzia, a first-ever drug for the treatment of peanut allergy in children developed by Aimmune Therapeutics. Peanut allergy is a disorder in which the body's immune system incorrectly interprets even minute amounts of peanut as dangerous. Palforzia is oral immunotherapy used to prevent allergic responses, including anaphylaxis, from occurring as a result of accidental peanut exposure.​ Thus, such factors can lead to sustainable growth over the forecast period.

Competitive Landscape

Most of the allergy treatment products are manufactured by global key players. With more funds for research and better distribution systems, the market leaders established their positions in the market. Asia-Pacific is witnessing the emergence of some small players due to the rising awareness, which boosted the market’s growth.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 The Increasing Importance for Self-medication
4.2.2 Rising Incidence of Food Allergies Worldwide
4.2.3 Rising Investments by Manufacturers on the Development of Novel Allergic Treatments
4.3 Market Restraints
4.3.1 Rise in Preference Toward the Use of Biosimilars
4.3.2 Low Awareness of Allergy Immunotherapy (AIT) Among Patients
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 Type
5.1.1 Eye Allergy
5.1.2 Rhinitis
5.1.3 Asthma
5.1.4 Skin Allergy
5.1.5 Food Allergies
5.1.6 Other Allergies
5.2 Treatment
5.2.1 Anti-Allergy Drugs Antihistamines Corticosteroids Decongestants Other Drugs
5.2.2 Immunotherapy Sub-cutaneous Immunotherapy (SCIT) Sub-lingual Immunotherapy (SLIT)
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 ALK-Abello AS
6.1.2 AbbVie Inc.
6.1.3 Allergy Therapeutics
6.1.4 Bausch Health Companies Inc.
6.1.5 Alembic Pharmaceuticals Limited
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Nicox SA
6.1.8 GlaxoSmithKline PLC
6.1.9 Johnson & Johnson
6.1.10 Leti Pharma
6.1.11 Dermapharm Holding SE
6.1.12 Novartis International AG
6.1.13 Sanofi SA
6.1.14 Stallergenes Greer PLC
6.1.15 Teva Pharmaceutical Industries

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ALK-Abello AS
  • AbbVie Inc.
  • Allergy Therapeutics
  • Bausch Health Companies Inc.
  • Alembic Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd
  • Nicox SA
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Leti Pharma
  • Dermapharm Holding SE
  • Novartis International AG
  • Sanofi SA
  • Stallergenes Greer PLC
  • Teva Pharmaceutical Industries